NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
Clinical Trials
7 trialsNCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02982395 2019-08-30
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00384891 2014-10-07
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
Medical Enterprises Europe B.V.
Phase 3 Terminated